[
    [
        {
            "time": "2020-04-05",
            "orginal_text": "复星医药（02196.HK）：控股子公司获药品临床试验通知书",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股子公司",
                    "药品临床试验",
                    "通知书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "复星医药（02196.HK）：控股子公司获药品临床试验通知书",
            "scores": {
                "News_content": "复星医药（02196.HK）：控股子公司获药品临床试验通知书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-04-05",
            "orginal_text": "复星医药：重组抗CTLA-4全人单克隆抗体注射液临床试验获批",
            "features": {
                "keywords": [
                    "复星医药",
                    "重组抗CTLA-4",
                    "全人单克隆抗体",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "复星医药：重组抗CTLA-4全人单克隆抗体注射液临床试验获批",
            "scores": {
                "News_content": "复星医药：重组抗CTLA-4全人单克隆抗体注射液临床试验获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-04-05",
            "orginal_text": "复星医药（600196.SH）：重组抗CTLA-4全人单克隆抗体注射液获药品临床试验通知书",
            "features": {
                "keywords": [
                    "复星医药",
                    "重组抗CTLA-4",
                    "全人单克隆抗体",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "复星医药（600196.SH）：重组抗CTLA-4全人单克隆抗体注射液获药品临床试验通知书",
            "scores": {
                "News_content": "复星医药（600196.SH）：重组抗CTLA-4全人单克隆抗体注射液获药品临床试验通知书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-04-05",
            "orginal_text": "复星医药（02196.HK）完成发行3亿元超短期融资券",
            "features": {
                "keywords": [
                    "复星医药",
                    "超短期融资券",
                    "发行"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星医药（02196.HK）完成发行3亿元超短期融资券",
            "scores": {
                "News_content": "复星医药（02196.HK）完成发行3亿元超短期融资券",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-04-05",
            "orginal_text": "医保概念概念股近三日受18亿主力资金追捧",
            "features": {
                "keywords": [
                    "医保概念",
                    "主力资金",
                    "追捧"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医保概念概念股近三日受18亿主力资金追捧",
            "scores": {
                "News_content": "医保概念概念股近三日受18亿主力资金追捧",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-04-05",
            "orginal_text": "艾德证券期货：欧美疫情或进入拐点 市场二次探底后机会大于风险",
            "features": {
                "keywords": [
                    "艾德证券期货",
                    "欧美疫情",
                    "拐点",
                    "市场二次探底"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全球市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "艾德证券期货：欧美疫情或进入拐点 市场二次探底后机会大于风险",
            "scores": {
                "News_content": "艾德证券期货：欧美疫情或进入拐点 市场二次探底后机会大于风险",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-04-05",
            "orginal_text": "科技驱动破解融资难 构建普惠金融客户生态体系",
            "features": {
                "keywords": [
                    "科技驱动",
                    "融资难",
                    "普惠金融",
                    "生态体系"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "科技驱动破解融资难 构建普惠金融客户生态体系",
            "scores": {
                "News_content": "科技驱动破解融资难 构建普惠金融客户生态体系",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-04-05",
            "orginal_text": "【山证医药】医药行业周报（20200405）：新版《药品注册管理办法》正式发布，建议持续关注国产创新",
            "features": {
                "keywords": [
                    "山证医药",
                    "药品注册管理办法",
                    "国产创新"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "【山证医药】医药行业周报（20200405）：新版《药品注册管理办法》正式发布，建议持续关注国产创新",
            "scores": {
                "News_content": "【山证医药】医药行业周报（20200405）：新版《药品注册管理办法》正式发布，建议持续关注国产创新",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]